Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (592)	10/20/2003 5:39:28 PM
From: Icebrg	Read Replies (1) \| Respond to of 897

>>What do you think? It appears you've started to look at CTIC recently.>> Yes, I have bought some recently. Mainly because of Pixantrone (Novus Pharma) and Trisenox. Not the best timing it seems. I listened to the CC and the company claimed they were almost pleased with the reduction as it would make it possible to pump more Xyotax into their patients (i.e. more cycles). The Data Safety Board had suggested a reduction from 235 mg/m2 to 210, but the company decided that 175 mg/m2 was more suitable as that was what they had used in the past. For flirting with a disaster they seemed pretty upbeat. They will do a corresponding reduction for PS2 status patients in the Stellar 2 trial. I am sure there was some spin there, but they didn't seem to be very concerned about the incident. It is interesting that they broke the news today and not tomorrow when they publish their results. Erik